<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645839</url>
  </required_header>
  <id_info>
    <org_study_id>DEPOSEIN-1008</org_study_id>
    <secondary_id>2010-023134-23</secondary_id>
    <nct_id>NCT01645839</nct_id>
  </id_info>
  <brief_title>Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer</brief_title>
  <acronym>DEPOSEIN</acronym>
  <official_title>Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer. Randomized Phase III Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the neurological progression free survival with the
      use of an intrathecal chemotherapy with liposomal cytarabine (DepoCyte®) in leptomeningeal
      metastasis of breast cancer (versus no intrathecal treatment).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients eligible for the trial and having signed their consent to participate will be
      randomized to arm A or B.

        -  Arm A: Standard systemic treatment without Depocyte®

        -  Arm B: Standard systemic treatment with Depocyte®

      Patients randomized to arm B will receive an intrathecal injection of Depocyte® every 14 ± 2
      days for a total of 5 cycles and then every 28 days until progression. The treatment should
      begin in the days following the randomization (maximum 10 days).

      The nature of the standard systemic treatment (chemotherapy, hormone therapy or targeted
      therapy) will be left to the discretion of the investigator according to the subtype of the
      breast cancer and according to the treatments already received. It will be determined prior
      to randomization. It can be amended at any time upon notice of the patient's referent
      oncologist. A focal radiotherapy on symptomatic sites can also be performed if necessary.

      Patients will have :

        -  a clinical assessment within 3 days prior to the start of the study treatment, every 2
           weeks for 2 months, then once a month until progression, and at the end of the study ;

        -  a paraclinical assessment within 14 days prior to the start of the study treatment,
           every 2 months, and at the end of the study ;

        -  and a biologic assessment within 7 days prior to the start of the study treatment, once
           a month until progression, and at the end of the study.

      They will likewise undergo a lumbar puncture prior to the start of treatment, once a month
      for patients in arm A, every 2 weeks for 2 months, then once a month until progression for
      patients in arm B and finally at the end of the study.

      They will also address questionnaires within 3 days prior to the start of the study
      treatment, every 2 weeks for 2 months, then once a month until progression and at the end of
      the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological Progression Free Survival</measure>
    <time_frame>At baseline</time_frame>
    <description>Time between the date of randomization and the date of first neurological progression (or the date of death if it comes first).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological Progression Free Survival</measure>
    <time_frame>Every 2 weeks for 2 months</time_frame>
    <description>Time between the date of randomization and the date of first neurological progression (or the date of death if it comes first).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological Progression Free Survival</measure>
    <time_frame>After 2 months from baseline once a month until progression (up to 6 months)</time_frame>
    <description>Time between the date of randomization and the date of first neurological progression (or the date of death if it comes first).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological Progression Free Survival</measure>
    <time_frame>At the end of the study (up to 6 months)</time_frame>
    <description>Time between the date of randomization and the date of first neurological progression (or the date of death if it comes first).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and timepoint of neurological, physical, cognitive, cytological and radiological improvement.</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and timepoint of neurological, physical, cognitive, cytological and radiological improvement.</measure>
    <time_frame>Every two weeks for 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and timepoint of neurological, physical, cognitive, cytological and radiological improvement.</measure>
    <time_frame>After 2 months from baseline once a month until progression (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and timepoint of neurological, physical, cognitive, cytological and radiological improvement.</measure>
    <time_frame>At the end of the study (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression free survival</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression free survival</measure>
    <time_frame>Every 2 weeks for 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression free survival</measure>
    <time_frame>After 2 months from baseline once a month until progression (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression free survival</measure>
    <time_frame>At the end of the study (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytological progression free survival</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytological progression free survival</measure>
    <time_frame>Every 2 weeks for 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytological progression free survival</measure>
    <time_frame>After 2 months from baseline once a month until progression (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytological progression free survival</measure>
    <time_frame>At the end of the study (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression free survival</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression free survival</measure>
    <time_frame>Every 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression free survival</measure>
    <time_frame>At the end of the study (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance to DepoCyte® according to NCI CTCAE V4.0</measure>
    <time_frame>Up to 30 days after the last administration of the study treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Research and quantification of tumor cells in the CSF by the Veridex technique for the diagnosis and monitoring of meningeal metastasis of breast cancer.</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Research and quantification of tumor cells in the CSF by the Veridex technique for the diagnosis and monitoring of meningeal metastasis of breast cancer.</measure>
    <time_frame>Every 2 weeks for 2 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Research and quantification of tumor cells in the CSF by the Veridex technique for the diagnosis and monitoring of meningeal metastasis of breast cancer.</measure>
    <time_frame>After 2 months from baseline once a month until progression (up to 6 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Research and quantification of tumor cells in the CSF by the Veridex technique for the diagnosis and monitoring of meningeal metastasis of breast cancer.</measure>
    <time_frame>At the end of the study (up to 6 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (questionnaire QLQ C30, BN20 and C15)</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (questionnaire QLQ C30, BN20 and C15)</measure>
    <time_frame>Every 2 weeks for 2 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (questionnaire QLQ C30, BN20 and C15)</measure>
    <time_frame>After 2 months from baseline once a month until progression (up to 6 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (questionnaire QLQ C30, BN20 and C15)</measure>
    <time_frame>At the end of the study (up to 6 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Autonomy in daily life (questionnaire Instrumental Activities in Daily Living)</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Autonomy in daily life (questionnaire Instrumental Activities in Daily Living)</measure>
    <time_frame>Every 2 weeks for 2 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Autonomy in daily life (questionnaire Instrumental Activities in Daily Living)</measure>
    <time_frame>After 2 months from baseline once a month until progression (up to 6 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Autonomy in daily life (questionnaire Instrumental Activities in Daily Living)</measure>
    <time_frame>At the end of the study (up to 6 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Emotional state of the patient assessed by the psychological distress score</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Emotional state of the patient assessed by the psychological distress score and the Patients' Global Impression of Change (PGIC) scale.</measure>
    <time_frame>Every 2 weeks for 2 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Emotional state of the patient assessed by the psychological distress score and the Patients' Global Impression of Change (PGIC) scale.</measure>
    <time_frame>After 2 months from baseline once a month until progression (up to 6 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Emotional state of the patient assessed by the psychological distress score and the Patients' Global Impression of Change (PGIC) scale.</measure>
    <time_frame>At the end of the study (up to 6 months)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Systemic treatment with Depocyte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrathecal injection of Liposomal Cytarabine (Depocyte®) every 14 ± 2 days for a total of 5 cycles and then every 28 ± 4 days until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic treatment without Depocyte</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intrathecal injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Cytarabine</intervention_name>
    <description>50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.</description>
    <arm_group_label>Systemic treatment with Depocyte</arm_group_label>
    <other_name>Depocyte</other_name>
    <other_name>Aracytine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive breast cancer.

          -  New diagnosis of leptomeningeal involvement confirmed by CSF cytology or clinical
             signs and symptoms associated with abnormal MRI features.

          -  MRI criteria : meningeal metastasis &lt; 0.5 cm or &gt; 0.5 cm in case of focused radiation
             therapy.

          -  Patient requiring a systemic treatment (chemotherapy and / or targeted therapy and /
             or hormone therapy) at the time of inclusion. The systemic treatment is left to the
             discretion of the investigator in connection with the referent senologist according
             to the characteristics of the cancer, the previous treatments received and the
             clinical and biological general state. Focused radiotherapy is authorized.

          -  Age ≥ 18 years

          -  Performance Status (ECOG) ≤ 2. Patients unable to walk due to paralysis but moving in
             wheelchairs are considered to be ambulatory.

          -  Life expectancy &gt; 2 months. Patients with a rapidly progressive systemic disease are
             not eligible for this protocol.

          -  Brain metastasis allowed if asymptomatic.

          -  In case of suspicion of a CSF blocking, or after local radiotherapy for lifting a CSF
             blocking, a study of the flow of CSF has to be performed (isotopic method) to confirm
             the absence of a CSF flow blocking.

          -  Patients must have recovered from the acute toxic effects of other cancer treatments
             received.

          -  Adequate hematological, renal, hepatic parameters :

               -  Total bilirubin ≤ 3 times the upper limit of normal (ULN).

               -  SGOT/AST ≤ 2.5 ULN ; ≤ 5 ULN if hepatic metastasis

          -  Effective contraceptive method (CPMP/ICH/286/95) for non menopausal patients (eg
             intrauterine device (IUD), sexual abstinence, vasectomized partner ) (no hormonal
             contraception).

          -  Patients having a social security scheme.

          -  Informed consent form signed by the patient.

        Exclusion Criteria:

          -  Leptomeningeal metastasis other than from breast cancer.

          -  History of other cancer ( &lt; 5 years) except cervix carcinoma, basal cell or squamous
             cell skin carcinoma properly treated.

          -  Contraindication to MRI (including claustrophobia)

          -  MRI criteria : CSF flow obstruction (hydrocephalus in brain MRI or obstacle in spinal
             MRI)

          -  Contraindication to lumbar puncture and to ventricular catheterization.

          -  Progressive brain metastasis requiring a total brain radiation therapy.

          -  History of craniospinal radiotherapy (History of focal or whole brain radiation
             therapy for parenchymal metastasis accepted).

          -  History of intrathecal treatment (lumbar or ventricular).

          -  History of systemic treatment with ARA-C or high-dose systemic methotrexate.

          -  Intravenous high dose concomitant treatment with methotrexate.

          -  Ventriculoperitoneal shunt.

          -  Active infection (systemic or cerebromeningeal).

          -  Hypersensitivity to ARA-C or DepoCyte.

          -  Other severe or non controlled pathology which could jeopardize the participation in
             the trial (infection, cardiovascular, digestive, renal, pulmonary disease).

          -  Patient already included in another therapeutic trial with an experimental molecule
             (within 30 days before the screening visit).

          -  Pregnant or breastfeeding women. Women must not breast-feed for at least 6 months.

          -  Patients unable to undergo medical follow up for geographic, social or psychological
             reasons.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie LERHUN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie LERHUN, MD</last_name>
    <phone>+33 (0)320295959</phone>
    <email>e-lerhun@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie TAILLIBERT, MD</last_name>
    <email>sophie.taillibert@psl.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Groupe Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu BOONE, MD</last_name>
      <email>boone.mathieu@chru-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu BOONE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno CHAUFFERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine PIPROT-CHAUFFAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François DUCRAY, MD</last_name>
      <email>francois.ducray@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>François DUCRAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie CARTALAT-CAREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure THOMAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme HONORAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine TOMMASI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre G.F. Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle DESMOULINS, MD</last_name>
      <email>idesmoulins@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle DESMOULINS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno COUDERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Séverine GUIU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre FUMOLEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>E. VIEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>S. LADOIRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>V. LORGIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>A. HERVIEU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mireille MOUSSEAU, MD, PhD</last_name>
      <phone>04 76 76 54 51</phone>
      <email>mmousseau@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Mireille MOUSSEAU, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu LARAMAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina COSTAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine REBISCHUNG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oxana SHESTAEVA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oana COJOCARASU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Oana COJOCARASU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie DENIZON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie LERHUN, MD</last_name>
      <phone>+33 (0)320295959</phone>
      <email>e-lerhun@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie LERHUN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques BONNETERRE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence VANLEMMENS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey MAILLIEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique SERVENT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine LAURIDANT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joëlle EGRETEAU, MD</last_name>
      <email>j.egreteau@ch-bretagne-sud.fr</email>
    </contact>
    <investigator>
      <last_name>Joëlle EGRETEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Régine LAMY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle CUMIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian SIRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel FABBRO, MD</last_name>
      <email>mfabbro@montpellier.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Michel FABBRO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna DURIGOVA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles ROMIEU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amélie DARLIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>S. POUDEROUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. LAIGRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>N. FIRMIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine LEBRUN FRENAY, MD</last_name>
      <email>lebrun-frenay.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Christine LEBRUN FRENAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique BOURG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esma SAADA-BOUZID, MD</last_name>
    </contact>
    <investigator>
      <last_name>Esma SAADA-BOUZID, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe FOLLANA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc FERRERO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc FRENAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augusti ALENTORN, MD</last_name>
      <phone>01 42 16 41 60</phone>
      <email>agusti.alentorn@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie TAILLIBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline DEHAIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline HOUILLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed IDBAIH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dimitrios PSIMARAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc SANSON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves DELATTRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence LAIGLE-DONADEY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khê HOANG-XUAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Augusti ALENTORN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maya GUTIERREZ, MD</last_name>
      <email>gutierrez@crh1.org</email>
    </contact>
    <investigator>
      <last_name>Maya GUTIERREZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fawzia MEFTI-LACHERAF, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 28, 2016</lastchanged_date>
  <firstreceived_date>July 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leptomeningeal metastasis</keyword>
  <keyword>Intrathecal chemotherapy</keyword>
  <keyword>Depocyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
